Neuromedin U

What is Neuromedin U?

Neuromedin U (NMU) is an endogenous neuropeptide isolated from porcine spinal cord in 1985 by Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute in Osaka — the same laboratory that would later isolate ghrelin, atrial natriuretic peptide, and other landmark gut and cardiovascular peptides. The peptide was named 'neuromedin U' for its potent stimulation of uterine smooth-muscle contraction in the original isolation assay (the 'U' standing for uterus). Two physiologically active forms exist: NMU-8, an octapeptide, and NMU-25, a 25-residue peptide with the NMU-8 sequence at its C-terminus. The C-terminal pentapeptide F-R-P-R-N-NH2 is the receptor-binding pharmacophore, conserved across species and required for receptor activation. NMU is processed from a 174-residue prepropeptide encoded by the NMU gene on human chromosome 4q12. NMU signals through two G-protein-coupled receptors of the rhodopsin family — NMUR1 (formerly FM3, GPR66) and NMUR2 (formerly FM4) — both deorphanized in 2000 by three independent laboratories almost simultaneously: Howard and colleagues at Merck (Nature 2000), Hosoya and colleagues at Takeda (J Biol Chem 2000), and Szekeres and colleagues at SmithKline Beecham (J Biol Chem 2000). NMUR1 is expressed predominantly in peripheral tissues (gastrointestinal tract, immune cells, lung, testis), while NMUR2 is enriched in the central nervous system, particularly the paraventricular nucleus of the hypothalamus and other feeding-related circuits — an anatomical split that has guided drug-development strategies. The dominant physiological roles of NMU are anorectic (suppression of food intake through central NMUR2 signaling), prokinetic (stimulation of gastrointestinal smooth muscle), pressor (acute hypertension when administered systemically), circadian (modulation of the suprachiasmatic-nucleus oscillator and feeding rhythms), stress-response (interaction with the HPA axis), and immune (driving Th2 inflammation in lung and gut, particularly in the context of helminth infection and allergic asthma). NMU has not been clinically developed as a therapeutic, but it remains an active drug target — particularly for obesity (NMUR2-selective central agonism), inflammatory bowel disease (NMUR1-selective antagonism), and asthma.

What Neuromedin U Is Investigated For

Neuromedin U is an endogenous-biology and drug-target topic, not a peptide consumers take. Its translational profile runs across four converging areas. First, the anorectic biology: when the NMU receptor pair (NMUR1, NMUR2) was deorphanized in 2000 by three independent laboratories in nearly simultaneous publications, the Merck group's Nature paper specifically identified central NMU as a feeding-suppressing peptide acting through NMUR2 in the paraventricular hypothalamus. Hanada and colleagues (Nature Medicine 2004) extended this with NMU-overexpressing mice showing a lean phenotype and NMU-deficient mice showing late-onset obesity, establishing NMU as a true endogenous regulator of body weight. NMUR2-selective agonism remains a candidate anti-obesity strategy, with research-stage agonists characterized but no clinical-stage assets. Second, the circadian biology: Nakahara and colleagues (BBRC 2004) demonstrated that NMU is involved in the mammalian suprachiasmatic-nucleus circadian oscillator, particularly in the entrainment of feeding rhythms — a finding that has positioned NMU as one of the bridges between metabolism and circadian timing. Third, the immunology: NMU has emerged as a driver of Th2-skewed inflammation through NMUR1 signaling on type-2 innate lymphoid cells in the lung and gut, with implications for asthma and helminth-driven gastrointestinal immunity. Fourth, the GI smooth-muscle and pressor biology: the original 'U' (uterus) name reflects NMU's potent stimulation of uterine and gastrointestinal smooth-muscle contraction, and NMU produces acute hypertension when administered systemically. The honest framing is that NMU has an unusually broad and integrated preclinical literature — feeding, circadian, immune, autonomic — but the translational chapter has not been written. The peptide nature of NMU and the difficulty of developing brain-penetrant NMUR2-selective agonists with adequate CNS exposure have repeatedly slowed obesity drug development; the immune and asthma applications remain at earlier stages. As of 2026, no NMU-targeted drug has reached approval.

History & Discovery

Neuromedin U was isolated in 1985 by Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute in Osaka, Japan — the same group that would go on to isolate ghrelin, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), neuromedin S, and other landmark gut, brain, and cardiovascular peptides over the following two decades. The NMU isolation used porcine spinal cord as the source tissue and uterine smooth-muscle contraction as the bioassay readout. The team purified two physiologically active forms of the peptide — NMU-8 (an octapeptide) and NMU-25 (a 25-residue peptide with the NMU-8 sequence at its C-terminus) — and named the peptide 'neuromedin U' for its potent stimulation of uterine contraction. The 1985 BBRC paper introduced the peptide to the field. The same Osaka group sequenced and characterized other 'neuromedin' peptides (B, C, K, N, S) in nearby publications, with each name reflecting the bioassay readout used in its initial isolation rather than its eventual physiological role. The receptor pharmacology of NMU was unresolved for fifteen years after the original isolation. Two orphan G-protein-coupled receptors with sequence similarity to other GI-peptide receptors — initially designated FM3 and FM4 — were known to exist but had no identified endogenous ligand. The remarkable triple-publication of 2000 — Howard and colleagues at Merck (Nature), Hosoya and colleagues at Takeda (Journal of Biological Chemistry), and Szekeres and colleagues at SmithKline Beecham (Journal of Biological Chemistry) — appeared in close succession and established that NMU is the endogenous ligand for both FM3 (renamed NMUR1) and FM4 (renamed NMUR2). The Howard Nature paper went further by demonstrating that intracerebroventricular NMU suppresses food intake in rats, identifying NMU as a previously unrecognized anorectic neuropeptide. This dual achievement — receptor identification and functional discovery of a feeding-related role — launched the modern era of NMU research. The genetic mouse evidence followed quickly. Hanada and colleagues (Nature Medicine 2004), working at the National Cardiovascular Center in Osaka and at Imperial College London (Stephen Bloom's group), reported that NMU-overexpressing mice show a lean phenotype with reduced food intake and increased energy expenditure, while NMU-deficient mice develop late-onset obesity with hyperphagia. This established endogenous NMU as a regulator of body weight, distinct from and independent of leptin signaling. Egecioglu and colleagues (Am J Physiol Endocrinol Metab 2009) extended the genetic evidence with NMUR2-deletion mice and chronic central NMU administration studies, providing additional support for the NMU/NMUR2 axis in body-weight control. The circadian biology of NMU developed in parallel through the work of Kenji Kangawa's group and others. Nakahara and colleagues (BBRC 2004) established NMU's involvement in the mammalian suprachiasmatic-nucleus circadian oscillator, particularly in the entrainment of feeding rhythms. The related peptide neuromedin S (NMS), identified in 2005 by Mori, Miyazato, Ida, Murakami, Iemura, Ueno, and Kangawa, was shown to share NMUR2 binding with NMU and to be enriched in the suprachiasmatic nucleus, suggesting a paralog division of labor in which NMS may be the dominant endogenous NMUR2 ligand for central circadian timing while NMU dominates in feeding and peripheral signaling. The immune chapter of NMU biology developed largely after 2015, when multiple independent laboratories established the neuron-to-ILC2 NMU signaling axis as a major regulator of mucosal Th2 immunity. NMU produced by enteric neurons activates type-2 innate lymphoid cells in the lung and gut through NMUR1, driving IL-5/IL-13 production, eosinophil recruitment, and goblet-cell hyperplasia — the canonical Th2 inflammatory profile relevant to allergic asthma and helminth-driven gut immunity. This immune-system role of NMU was not anticipated at the time of the 1985 isolation or the 2000 receptor deorphanization, and it has substantially expanded the therapeutic interest in NMU pathway modulation. The translational chapter of NMU has been slower than the basic-science progress would suggest. Selective NMUR2 agonists for obesity have faced the typical challenges of brain-penetrant peptide GPCR agonist development; selective NMUR1 antagonists for asthma and inflammatory bowel disease are in earlier-stage exploration. As of 2026, no NMU-targeted drug has reached approval, despite a richly developed multidisciplinary preclinical literature and a peptide-receptor system with one of the cleaner mechanistic stories in modern neuropeptide research. The dominant current weight-loss drug class — GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) — has reached approval ahead of NMU-based approaches, but NMUR2 agonism remains a candidate for next-generation combination obesity pharmacotherapy.

How It Works

Neuromedin U is a small protein your nervous system uses as a chemical messenger. It does several different jobs depending on where it acts. In the brain, it tells you to stop eating — mice without NMU get fat as they age, and mice with extra NMU stay lean. It also helps your body sync feeding to your circadian (day/night) rhythm. In your gut and lungs, NMU activates a group of immune cells called type-2 innate lymphoid cells, which contributes to allergic asthma and to the immune response against parasitic worms. NMU also makes uterine and gut smooth muscle contract — that's actually how it was first discovered in 1985, and it's why the 'U' in its name stands for uterus. Drug companies are interested in NMU receptor agonists for obesity (the brain receptor, NMUR2) and antagonists for asthma and inflammatory bowel disease (the body receptor, NMUR1), but no NMU-targeted drug has reached approval.

Neuromedin U exists in two physiologically active forms: NMU-8, an octapeptide (sequence YFLFRPRN-NH2 in human, with C-terminal amidation), and NMU-25, a 25-residue peptide containing the NMU-8 sequence at its C-terminus. Both are processed from a 174-residue prepropeptide encoded by the NMU gene on human chromosome 4q12. The C-terminal pentapeptide F-R-P-R-N-NH2 is the receptor-binding pharmacophore, conserved across species and required for receptor activation. NMU is expressed broadly in central and peripheral tissues, with particularly high expression in the gastrointestinal tract (small intestine, colon), enteric neurons, anterior pituitary, hypothalamic nuclei (arcuate, paraventricular, dorsomedial), brainstem (nucleus of the solitary tract), spinal cord, and testis. NMU signals through two G-protein-coupled receptors of the rhodopsin family — NMUR1 (formerly FM3, GPR66) and NMUR2 (formerly FM4) — both cloned and deorphanized in 2000 by three independent laboratories almost simultaneously. The Merck group (Howard, Wang, Feighner, and colleagues) reported NMUR2 as the central feeding-related receptor in their Nature paper, the Takeda group (Hosoya, Moriya, Miyamoto, and colleagues) reported NMUR2 (their 'orphan FM4') in Journal of Biological Chemistry, and the SmithKline Beecham group (Szekeres, Muir, Spinage, and colleagues) reported NMUR1 (their 'orphan FM3') in the same journal. The remarkable triple-publication of NMU receptor pharmacology in 2000 launched the modern era of NMU drug discovery. Receptor coupling and anatomical distribution differ markedly between subtypes. NMUR1 is expressed predominantly in peripheral tissues — gastrointestinal tract, immune cells (particularly type-2 innate lymphoid cells), lung, testis, kidney, with limited central expression — and couples primarily to Gq/11 with phospholipase C activation and intracellular calcium mobilization. This receptor mediates NMU's gastrointestinal smooth-muscle contractile effects, the original uterotonic activity that gave NMU its name, and the more recently characterized Th2 immune signaling on ILC2s in lung and gut mucosal immunity. NMUR2 is enriched in the central nervous system, particularly the paraventricular nucleus and arcuate nucleus of the hypothalamus, the dorsomedial hypothalamus, the nucleus of the solitary tract, and the suprachiasmatic nucleus — and it couples to both Gq/11 and Gi/o pathways. This receptor mediates NMU's anorectic and circadian effects. Functionally, central NMU acting at NMUR2 in the paraventricular and other hypothalamic nuclei suppresses food intake. Howard's 2000 Nature paper demonstrated this directly; Hanada and colleagues (Nature Medicine 2004) extended it with the foundational genetic-mouse data showing that NMU-overexpressing mice are lean and NMU-deficient mice develop late-onset obesity, establishing endogenous NMU as a true regulator of body weight. Egecioglu and colleagues (Am J Physiol Endocrinol Metab 2009) characterized NMUR2-deletion mice and chronic central NMU administration, providing additional evidence for central NMU/NMUR2 signaling in body-weight regulation. Nakahara and colleagues (BBRC 2004) demonstrated NMU's involvement in the mammalian suprachiasmatic-nucleus circadian oscillator, particularly in feeding-rhythm entrainment. NMU also interacts with the hypothalamic-pituitary-adrenal stress axis through paraventricular CRH neurons, with central NMU producing CRH-mediated stress responses in some paradigms. Peripheral NMU acting at NMUR1 produces gastrointestinal smooth-muscle contraction, acute hypertension when administered systemically (an effect noted in the original 1985 isolation), and Th2-skewed immune activation through ILC2s. The neuron-to-ILC2 NMU signaling axis emerged as a major area of mucosal immunity research from 2017 onward, with implications for allergic asthma, helminth-driven gut immunity, and IBD. NMU is one of the clearest examples of a neuropeptide that bridges the enteric nervous system and mucosal immune regulation. The related peptide neuromedin S (NMS) was identified in 2005 by Mori and colleagues as an additional ligand of NMUR2, sharing the C-terminal F-R-P-R-N-NH2 motif with NMU and producing largely overlapping central effects on feeding and circadian biology. NMS is enriched in the suprachiasmatic nucleus and may be the dominant endogenous NMUR2 ligand in central circadian timing, while NMU dominates in feeding and peripheral signaling — a paralog division of labor that adds complexity to selective receptor pharmacology.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Neuromedin U:

• 01Whether brain-penetrant NMUR2-selective agonists can deliver sustained anorectic effects in humans without engaging peripheral NMUR1-mediated cardiovascular or immune effects — the central translational question for NMU as an obesity drug.
• 02Whether NMUR1-selective antagonists can deliver clinical benefit in asthma, allergic disease, or inflammatory bowel disease without unintended consequences in helminth immunity, gut motility, or stress responses.
• 03The relative roles of NMU and NMS as endogenous NMUR2 ligands in feeding versus circadian timing — whether the two paralogs operate redundantly or with division of labor has implications for selective drug development.
• 04Whether the neuron-to-ILC2 NMU signaling axis represents a viable therapeutic node for mucosal immune disease, or whether redundancy with other neural-immune signals (CGRP, VIP, substance P) limits the therapeutic window.
• 05The role of NMU in human energy expenditure and thermogenesis — Hanada's mouse data showed effects on both food intake and energy expenditure, but the human contribution of NMU to thermogenic regulation is uncharacterized.
• 06Whether NMU-pathway modulation has implications for circadian-related metabolic disease (shift-work obesity, jet-lag-induced insulin resistance) given the established NMU role in feeding-rhythm entrainment.
• 07The dynamics and clinical relevance of plasma NMU in human metabolic disease, sepsis, asthma exacerbations, and other clinical states where the underlying NMU biology suggests possible biomarker utility.

Forms & Administration

Neuromedin U is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic NMU-8 and NMU-25 for in vitro NMUR1 and NMUR2 binding and signaling assays, ex vivo tissue pharmacology, intracerebroventricular and intraperitoneal administration in animal feeding and circadian studies, and ILC2-based mucosal immunity preparations. Selective small-molecule NMUR2 agonists (for obesity research) and NMUR1 antagonists (for asthma and IBD research) exist as research tools, but no NMU-targeted drug has progressed to clinical-stage development as of 2026. Compounded NMU from peptide marketplaces has no validated clinical use.

Common Questions

Who Neuromedin U Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for NMU because no NMU product has been clinically developed. Theoretical interactions extrapolate from NMU's known signaling. Systemic NMU administration produces pressor responses and would interact with antihypertensive medications (diuretics, ACE inhibitors, ARBs, calcium-channel blockers) by opposing their blood-pressure-lowering effects. NMU's gastrointestinal smooth-muscle contractile activity could interact with prokinetics (metoclopramide, prucalopride, erythromycin, domperidone) by additive contractile effects, and with antimotility or antispasmodic agents by opposing effects. NMU's central anorectic activity could interact additively with other anorectic agents — including GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), amylin analogs (pramlintide), and PYY-based agents (eloralintide). NMU's Th2-skewed immune effects through NMUR1 could interact with biologic therapies for asthma (anti-IL-4/IL-13 agents like dupilumab, anti-IL-5 agents like mepolizumab) by opposing or amplifying their immunological effects. None of these interactions has been characterized for NMU in controlled clinical drug-interaction studies; they are mechanistic possibilities.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions